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Abstract 
Aims 
Older people with diabetes are susceptible to harm from hypoglycemia, however the 
consequences of hypoglycemia in older people with dementia are not known. We 
aimed to test association between hypoglycemia and serious adverse events in older 
patients with diabetes and dementia, and whether the consequences of 
hypoglycemia were affected by presence of dementia.  
Materials and Methods 
Cohort study using Clinical Practice Research Datalink in England (1997-2016).  We 
selected participants, intervention (exposure) and follow-up to mirror two hypothetical 
target randomised controlled trials.  Target trial 1’s exposure was hypoglycemia in 
patients with dementia. Target trial 2 examined adverse effects of hypoglycemia 
according to dementia status. 
We used Cox proportional hazard regression to estimate adjusted hazard ratios 
(aHR) for falls, fractures, cardiovascular events and mortality.    
Results 
In target trial 1, hypoglycemia was associated with an increased risk during 12 
months follow-up of falls and fractures - aHR 1.94 (95% CI 1.67 to 2.24), 
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cardiovascular events - aHR 2.00 (95% CI 1.61 to 2.48) and mortality - aHR 2.36 
(95% CI 2.09 to 2.67). 
In target trial 2, presence of dementia was associated with increased risk of adverse 
events after hypoglycemia (12 months follow-up): falls & factures - aHR 1.72 (95% 
CI 1.51 to 1.96) and mortality - aHR 1.27 (95% CI 1.15 to 1.41), but had no effect on 
cardiovascular events - aHR 1.14 (95% CI 0.95 to 1.36).   
 
Conclusions and Relevance 
Hypoglycemia is associated with an early increased risk of serious adverse events in 
older people with diabetes and dementia. 
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Introduction 
Worldwide, there are 425 million people living with diabetes and this is expected to 
rise to 629 million by 2045 (1).  It is also estimated that around 50 million people 
across the world are living with dementia, which is expected to rise to 125 million by 
2050 (2).  These projections indicate that comorbid diabetes and dementia is likely to 
pose a major healthcare burden, given 13-20% of people with dementia also have 
diabetes (3).   
 
Self-management of diabetes is particularly challenging for older patients because 
they have limited recall of the dangers of hypoglycemia and what remedial action to 
take (4), and because they are more prone to hypoglycemia from their medication (5) 
(6). The burden of hypoglycemia in older patients has steadily mounted (7) (8) (9), 
with one study reporting a 267% increase in hypoglycemia hospitalizations for 
patients aged 75 years or older in England and Wales (2000-2014), and a 10-fold 
higher admission rate compared to patients in the 15-59 years age group (7). A 
worldwide study of 109 countries found a 60% increase in hypoglycemia-related 
deaths between 2000-2010, with these deaths occurring mainly in individuals over 
the age of 50 years (10).  
Other studies involving older people with diabetes have identified potentially serious 
consequences (e.g. cardiovascular events, falls, fractures and death) that extend 
beyond the acute event of hypoglycemia alone(6). However, most of the studies 
have not specifically focused on these hypoglycemia-related complications in older 
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people with dementia, although there is evidence from a recent meta-analysis that 
patients with diabetes and dementia may be even more prone to hypoglycemia and 
subsequent cognitive complications (11). 
 
Hypoglycemic events are known to have serious consequences including falls and 
fractures and are associated with earlier mortality (6).  However, the specific risks 
associated with hypoglycemia among older people with dementia are not well 
understood.  A more comprehensive understanding of the consequences of 
hypoglycaemia in this vulnerable and complex group will help optimise the clinical 
management. 
Our overall aim was to test the effect of hypglycemia in older people with dementia 
and diabetes on serious adverse events, specifically cardiovascular events 
(myocardial infarction, ischemic stroke), falls and fractures, and all-cause mortality.  
We also examined whether dementia modified the effect of hypoglycemia. 
 
Materials and Methods 
Study design 
We performed a retrospective cohort study using data from the Clinical Practice 
Research Datalink (CPRD) database. We designed two hypothetical target trials 
within a cohort of older patients with diabetes. The first target trial aimed to test the 
effect of hypoglycemia among people with dementia and diabetes, with respect to 
subsequent serious adverse events.  We also conducted a second target trial to 
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evaluate whether the effect of hypoglycemia was affected by the presence or 
absence of dementia.  We selected participants, intervention (exposure) and follow-
up to mirror the two hypothetical target randomised controlled trials (12) (see Figure 
1).    
 
 
Study data and Setting 
CPRD holds anonymised primary care records from general practitioners (GPs), 
encompassing over 11 million patients from 674 practices in the United Kingdom 
(UK) and is broadly representative of the UK general population in terms of age, sex 
and ethnicity (13). A subset of primary care datasets is also linked with Hospital 
Episode Statistics (HES), which covers emergency department (ED) attendance and 
hospitalization, the Office for National Statistics (ONS), which covers mortality data, 
and the Index of Multiple Deprivation and Townsend scores (deprivation scores) 
(13).   
The study protocol was approved by the Independent Scientific Advisory Committee 
(ISAC) – protocol number 16_184R. 
We followed the Strengthening the Reporting of Observation Studies in 
Epidemiology (STROBE) guidelines (14). 
 
Participants 
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The cohort consisted of patients aged 65 or older with diabetes, defined as a first 
ever prescription of any oral or injectable glucose-lowering agent between April 1997 
and March 2016.  We considered initiation of a glucose-lowering drug to be a proxy 
for diagnosis and treatment of diabetes mellitus because there are no other clinical 
indications (e.g. polycystic ovary syndrome) for such drugs in this age group. 
 
Eligible participants also needed HES-linked data available. Dementia status was 
ascertained based on presence of CPRD Read Code or HES International 
Classification of Diseases and Related Health Problems (ICD) code (Supplemental 
Table S5).  Read Codes have been used by the National Health Service (NHS) since 
the 1980s and are a thesaurus of clinical terms. 
 
Exposure and Outcomes 
The exposure was defined as the first hypoglycemic episode recorded on the 
primary (CPRD) or secondary (HES) healthcare database from April 1997 onwards 
following initiation of a glucose-lowering agent.  Data on hypoglycemic episodes 
were obtained from CPRD using Read codes and HES with ICD codes 
(Supplemental Table S5).  Combined use of CPRD and HES broadens the capture 
of hypoglycemia to include events recorded by medical personnel in both the primary 
and secondary care settings; a similar approach has been used in previous research 
on the association between hypoglycemia and cardiovascular events in insulin users 
(15). 
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For target trial 1, the exposed group’s (dementia, hypoglycemia) first coded 
hypoglycemic episode occurred a median (IQR) of 13 (2-34) months after meeting 
the study eligibility criteria.  For the control group (dementia, no hypoglycemia), we 
added a random lag to the date of first meeting study criteria to define their point of 
exposure (or index date for start of follow-up for adverse events) by randomly 
sampling the delay between first meeting the study eligibility criteria and the first 
hypoglycemic episode in the exposed group (16).   
 
The outcomes were falls, fractures, cardiovascular events (myocardial infarction, 
ischemic stroke) and all-cause mortality. In addition, we assessed the rate of 
Emergency Department attendances for patients who had their point of exposure 
after 1 April 2007 (HES Accident & Emergency data is only available for the time 
period April 2007 to 31 March 2016).   
The start of follow-up was the first hypoglycemic episode, or the randomly allocated 
exposure date for the control group in target trial 1.  Follow-up continued for up to 
five years from the exposure, loss from database, death, or end of available 
database linkage (HES 31 March 2016 and ONS 17 April 2017), whichever was the 
earlier.   
 
Covariates 
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We extracted information on a range of patient characteristics, including year of birth, 
gender, index of multiple deprivation quintile, year of glucose-lowering drug initiation, 
duration of dementia and diabetes, medications, co-morbid conditions (hypertension, 
peripheral vascular disease, valvular heart disease, cardiovascular disease, chronic 
kidney disease, atrial fibrillation), complications (severe kidney failure, amputation, 
blindness), body mass index (BMI), glycated hemoglobin (HbA1c) (17) (18).  
 
Covariates were measured at the point of exposure.  We took into account the 
medication history for the past 90 days, most recent BMI within the last three years 
and most recent HbA1c within the last 18 months. 
 
Statistical analysis 
To estimate the association between the timing of hypoglycemic episodes and 
defined outcomes, we used Cox proportional hazard regression models with 
adjustment for appropriate confounders to generate Hazard Ratios (HRs) and 95% 
Confidence Intervals (95% CI) for each outcome. We visually inspected log-log plots 
of survival to assess the proportional hazards assumption.  If the proportional hazard 
assumption was not met, we estimated the hazards at shorter and longer follow-up 
periods.  
 
We used complete-case analysis for both hypothetical target trials, because we 
could not be certain that data were missing at random or not. We carried out 
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sensitivity analyses using different methods (multiple imputation, use of a missing 
data category, and exclusion of lifestyle covariates). 
 
We used negative binomial regression to estimate the adjusted rate ratios of 
emergency department attendances for patients who had their point of exposure 
after 1 April 2007. 
 
Analyses were performed with STATA version 14.2 software (StataCorp LP, College 
Station, TX). 
 
Results 
Our cohort consisted of a total of 19,993 patients with diabetes (Figure 2).  Patient 
demographics are set out in Table 1.   The mean age of the dementia group was 82 
years and the non-dementia group was 77 years.  Insulin use was higher in those 
with dementia and hypoglycemia compared to those with dementia and no 
hypoglycemia (48% versus 13%). 
The proportional hazards assumption for the majority of the outcomes was not met in 
the statistical analysis, hence we stratified the analysis according to less than or 
more than 12 months of follow-up (Tables 2 and 3). 
 
The number of events is reported in Tables 2 and 3 and the median time to event is 
reported in Supplemental Table S3. 
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Target trial 1 – the effect of hypoglycemia on outcomes in patients with dementia 
(Table 2) 
During the first 12 months, adverse events occurred at about twice the rate among 
those with hypoglycemia compared to those without - all-cause mortality (aHR 2.36 
[95% CI 2.09 to 2.67]), cardiovascular events (aHR 2.00 [95% CI 1.61 to 2.48)] and 
falls and fractures (aHR 1.94 [95%CI 1.67 to 2.24]). 
 
Hypoglycemia was associated with an increase in subsequent myocardial infarction 
(MI) (aHR 2.24 [95% CI 1.59 to 3.15]) and ischemic stroke (aHR 1.80 [95% CI 1.37 
to 2.36]) among people with dementia.    Falls and fracture risks individually were 
also both increased (aHR 1.96 [95% CI 1.69 to 2.29] and aHR 1.62 [95% CI 1.25 to 
2.08]). 
 
However, the associations diminished with longer follow-up.  During the 12-60 
months follow-up, there remained an association with mortality (aHR 1.33 [95% CI 
1.19 to 1.48), but not the other outcomes. 
 
Target trial 2 – the effect of co-morbid dementia on outcomes in patients with 
hypoglycemia (Table 3) 
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During the first 12 months, co-morbid dementia was associated with an increased 
risk of falls and fractures (aHR 1.72 [95% CI 1.51 to 1.96]) and mortality (aHR 1.27 
[95% CI 1.15 to 1.41]) in older people with hypoglcyemia.   
The risk of mortality increased to more than double during the 12-60 months follow-
up period (aHR 2.15 [95% CI 1.94 to 2.37]). 
Dementia did not show a statistically significant association on cardiovascular events 
(aHR 1.14 [95% CI 0.95 to 1.36]).  It was associated with a significant increase in the 
risk of ischemic stroke (aHR of 1.41 [95% CI 1.12 to 1.78]), but not myocardial 
infarction (aHR 0.84 [95% CI 0.64 to 1.10]). 
 
Sensitivity analyses (Supplemental Tables S1 and S2) 
Certain lifestyle variables such as BMI, alcohol, smoking status and HbA1c were not 
regularly measured or necessarily measured close to the exposure.  Our findings did 
not substantially change when using different methods to account for the missing 
data.  
 
Emergency department attendances (Supplemental Table S4) 
The rate of ED attendances in patients with dementia and hypoglycemia was 113 per 
100 patient-years.  The rate in those with dementia but no hypoglycemia was 64 per 
100 patient-years (aRR 1.43 [95% CI 1.30 to 1.57]. 
 
Discussion 
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We have shown that older people with dementia and diabetes who have had a 
hypoglycemic event have substantially higher risk of death, cardiovascular events, 
falls, fractures and emergency department attendances, than those who have not.    
The hazard ratios of complications were found to be greatest within the first 12 
months of follow-up.  The magnitude of risk diminished with longer follow-up time, 
which indicates that our findings are probably not related to unmeasured 
confounders.  Persistent residual confounding would more likely be associated with 
constantly elevated hazard ratios across the entire duration. 
 
The results underscore the importance of management strategies tailored towards 
avoidance of hypoglycemic episodes rather than just chasing tight glycemic targets 
in this vulnerable group.  This is of particular significance in the light of recent 
findings that asymptomatic hypoglycemic episodes are often missed in older people 
with diabetes (19), as this study may only be looking at the tip of the iceberg 
regarding the impact of hypoglycemia.   
 
Furthermore, the higher risk in the first 12 months would be clinically consistent with 
the potential impact of an acute episode of hypoglycemia, especially if the underlying 
harm stems from cardiac damage.  For example, Pistrosch et al’s study of 
continuous glucose monitoring (CGM) and ambulatory cardiac monitoring found a 
link between hypoglycemia and the occurrence of ventricular arrhythmias (20).    A 
recently published meta-analysis confirmed that hypoglycemia can result in ECG 
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changes associated with cardiac arrhythmias that are markers of increased risk of 
mortality and cardiovascular events (21).  Cardiac arrhythmias may be an underlying 
factor to explain our findings of increased risk of myocardial infarction, stroke, falls 
and death following hypoglycemia.  Nevertheless, the effects of hypoglycemia on the 
cardiovascular physiology of frail, multi-morbid older patients with diabetes remains 
unclear.  
 
More recent studies estimated the link between hypoglycemia and accelerated 
cognitive decline.  Hypoglycemia in older people is linked to an increased risk in 
cognitive decline (11) and one recent study found that hypoglycemia was associated 
with smaller total brain volume on MRI (22). Cognitive decline may in turn pre-
dispose older frail people to falls, fractures and death following hypoglycemia.  This 
ties in with our findings that dementia contributes to greater hazards in terms of 
mortality, falls and fractures in older patients with hypoglycemia.   
 
However, the effect of co-existing dementia on subsequent risk of myocardial 
infarction in older people with hypoglycemia is unclear and diagnostic difficulty or 
misclassification may be a source of bias here. Older people with myocardial 
infarction can present with vague symptoms such as shortness of breath, nausea, 
sweating or collapse, which may result in them going unrecognised. Alexander et al 
found that only 40% of over 85-year-olds presented with the typical symptom of 
chest pain when experiencing an acute myocardial infarction (23) (24).  Patients with 
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co-morbid dementia may not be sufficiently able to communicate their symptoms, 
and symptoms such as shortness of breath and sweating could, for example, be 
misdiagnosed as pneumonia on initial presentation.  Bronchopneumonia is reported 
as the most common cause of death in older patients with dementia (25) (26).   
 
Strengths and limitations 
The strengths of this study include the size of the cohort of nearly 20,000 patients 
and the number of covariates that we used to address confounding.  We were aware 
that differences in patient characteristics and medication could be potentially 
important contributors to risk of adverse outcomes. Hence, our registered protocol 
specified the inclusion of several key variables (such as age, insulin use and co-
morbidities) to reduce confounding in the adjusted statistical model.  As we are 
presenting the results of an observational study, we are not able to prove a causal 
link, however, this study does demonstrate that hypoglycemia is a marker of risk for 
subsequent adverse events. 
 
We evaluated validity of our study against the domains listed in the ROBINS-I tool 
(27). The three areas which carry a moderate risk of bias are: confounding, missing 
data and classification of intervention. We are aware that in some patients, 
covariates such as BMI, HbA1c, smoking and alcohol status may not have been 
regularly documented in the preceding period before the exposure.  However, we 
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used three different methods to address this issue in our sensitivity analyses, all of 
which yielded similar results. 
 
Our findings are principally applicable to severe hypoglycemic events, which require 
medical assistance and hence result in an entry on an individuals’ medical records. 
Large trials have used the same methodology in assessing severe hypoglycemia 
and its complications, and our approach is therefore compatible with current 
research practice (28) (29) . We recognize that risk of subsequent complications may 
be of greater magnitude due to the severity of the hypoglycemia and we cannot 
determine whether self-managed or asymptomatic hypoglycemia are associated with 
a similar or lower risk of serious consequences.  However, in the absence of large 
CGM trials in older people with diabetes and dementia, there are no means of 
reliably detecting mild or asymptomatic hypoglycemic episodes for research 
purposes.  Hypoglycemic episodes documented in primary and secondary care 
healthcare records are currently the only available source. 
 
In addition, we are not able to accurately ascertain from the database the precise 
timing of the hypoglycemic episode and what the blood glucose concentrations were, 
although, by virtue of the fact that these hypoglycemic episodes have been recorded 
on the medical database, one would assume that they were of a severity that 
warranted being brought to the attention of the patient’s healthcare team. Moreover, 
we have not attempted to analyse the effects of recurrent hypoglycemia because 
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very few patients experienced recurrent events in previous studies using the same 
database (30) (31).    
Similarly, we are not able to accurately determine dementia severity or duration from 
onset due to the insidious onset and substantial variation in clinical presentation.   
 
A combination of less rigorous management regimes, but greater intensity of 
monitoring should be considered to reduce hypoglycemia in this vulnerable 
population.  Simply changing or loosening HbA1c targets for the older frail population 
may not help in reducing hypoglycemic events. The risk of hypoglycemia may also 
have some relationship to variability, rather than low absolute values of HbA1c, as 
demonstrated in a recent paper reporting that a slight change in HbA1c variability 
resulted in a more than five-fold risk of hospitalization due to hypoglycemia (30).   
Future research has to focus on a randomized controlled trial (in older people with 
diabetes and dementia), where the treatment strategy would be aimed at minimizing 
(or even eradicating) hypoglycemic episodes.  An essential component of the trial 
would be the use of CGM, in order capture hypoglycemic episodes that may 
otherwise go unrecorded and guide the hypoglycemia minimization strategy (by 
means of analysing ambulatory glucose profiles obtained through CGM), in addition 
to being a useful and supportive tool for carers in their day to day care of this 
vulnerable group of older people.  
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To sum up, hypoglycemia is associated with greater risk of subsequent 
complications such as falls, fractures and death in patients with dementia. 
Future work should focus on personalized management of diabetes and monitoring 
strategies in those with co-morbid dementia, aiming for an optimal balance of 
treatment effect whilst minimizing risk of hypoglycemia. 
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Figure legends 
 
Figure 1. Schematic presentation of study 
 
Figure 2. Patient flowchart 
  
This article is protected by copyright. All rights reserved.
   
 
  
 
Table 1. Baseline characteristics 
 
Dementia, no 
hypoglycemia 
(n=6134) 
Dementia, 
hypoglycemia 
(n=1679) 
Hypoglycemia, no 
dementia 
(n=12180) 
Characteristics    
Age (years), mean (SD) 81.61 (6.88) 82.77 (6.59) 76.97 (7.31) 
Male gender, n (%) 2600 (42.39) 691 (41.16) 6105 (50.12) 
Ethnicity, n (%)    
Asian 188 (3.1) 59 (3.5) 541 (4.4) 
Black 156 (2.5) 59 (3.5) 261 (2.1) 
White 5409 (88.2) 1489 (88.7) 10787 (88.6) 
mixed/other 29 (0.5) 9 (0.5) 45 (0.4) 
unknown 352 (5.7) 63 (3.8) 546 (4.5) 
Documented smoking history, n 
(%)    
Yes 2984 (48.65) 852 (50.74) 7300 (59.93) 
No 3150 (51.35) 827 (49.26) 4880 (40.07) 
Body mass index (kg/m2), mean 
(SD) 26.63 (5.29) 26.32 (5.15) 28.67 (5.92) 
IMD quintile score, mean (SD)  2.88 (1.37) 3.03 (1.38) 3.01 (1.36) 
Documented alcohol history, n 
(%)    
Yes 3638 (59.31) 964 (57.42) 8601 (70.62) 
No 2496 (40.69) 715 (42.58) 3579 (29.38) 
Hemoglobin A1c (mmol/L), mean 
(SD) 56.71 (17.10) 62.46 (20.89) 60.51 (17.74) 
Hemoglobin A1c (%), mean (SD) 7.3 (3.7) 7.9 (4.1) 7.7 (3.8) 
Diabetes therapy duration 
(years), mean (SD) 5.22 (5.53) 8.55 (6.66) 8.62 (5.77) 
Dementia duration (years), mean 
(SD) 1.64 (2.24) 1.90 (2.31) N/A 
Comorbidities, n(%)    
Atrial fibrillation 951 (15.50) 309 (18.40) 1829 (15.02) 
Blindness 385 (6.28) 132 (7.86) 873 (7.17) 
Chronic obstructive pulmonary 
disease 448 (7.30) 138 (8.22) 1442 (11.84) 
Heart failure 482 (7.86) 190 (11.32) 1583 (13.00) 
Liver disease 89 (1.45) 31 (1.85) 258 (2.12) 
Hypertension 4023 (65.59) 1101 (65.57) 8515 (69.91) 
Inflammatory bowel disease 78 (1.27) 23 (1.37) 176 (1.44) 
Neuropathies 195 (3.18) 103 (6.13) 693 (5.69) 
Osteoporosis 405 (6.60) 137 (8.16) 725 (5.95) 
Parkinsons disease 224 (3.65) 56 (3.34) 149 (1.22) 
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Peripheral vascular disease 247 (4.03) 111 (6.61) 829 (6.81) 
Valvular heart disease 150 (2.45) 60 (3.57) 363 (2.98) 
Renal disease 389 (6.34) 230 (13.70) 1524 (12.51) 
Rheumatoid arthritis 141 (2.30) 57 (3.39) 429 (3.52) 
Thyroid disease 884 (14.41) 267 (15.90) 1754 (14.40) 
Retinopathy 1438 (23.44) 653 (38.89) 4709 (38.66) 
Lower limb amputation 69 (1.12) 46 (2.74) 418 (3.43) 
Previous fractures 1143 (18.63) 397 (23.65) 1753 (14.39) 
Cancer that metastasizes to the 
bone 349 (5.69) 113 (6.73) 847 (6.95) 
History of previous MI 973 (15.86) 366 (21.80) 2643 (21.70) 
Prescription in past 90 days, n 
(%)    
Renin-angiotensin blockers 2790 (45.48) 825 (49.14) 7597 (62.37) 
Thiazide diuretic 763 (12.44) 137 (8.16) 2039 (16.74) 
Loop diuretics 1371 (22.35) 525 (31.27) 4165 (34.20) 
Betablocker 1304 (21.26) 367 (21.86) 3327 (27.32) 
Antiplatelets 3322 (54.16) 952 (56.70) 6367 (52.27) 
Anticoagulation 437 (7.12) 120 (7.15) 1154 (9.47) 
Lipid lowering medication 3608 (58.82) 974 (58.01) 7657 (62.87) 
Steroids 278 (4.53) 111(6.61) 1212 (9.95) 
Calcium channel blocker 1556 (25.37) 406 (24.18) 4011 (32.93) 
PD meds 216 (3.52) 54 (3.22) 185 (1.52) 
Antiarrhythmics 49 (0.80) 24 (1.43) 278 (2.28) 
Antidepressants 2006 (32.70) 598 (35.62) 2560 (21.02) 
Antipsychotics 904 (14.74) 253 (15.07) 468 (3.84) 
Hypnotics 429 (6.99) 121 (7.21) 565 (4.64) 
Drugs affecting bone metabolism 475 (7.74) 166 (9.89) 810 (6.65) 
Sulphonylureas 2511 (40.94) 786 (46.81) 5662 (46.49) 
Insulin 794 (12.94) 801 (47.71) 5974 (49.05) 
Other oral hypoglycemics 3512 (57.25) 678 (40.38) 5528 (45.39) 
Dementia drugs 1027 (16.74) 180 (10.72) Not applicable 
 
1Bisphosphonates, Calcitonin, Calcium and Vitamin D supplements 
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Table 2. Target trial 1 – effect of hypoglycemia in patients with diabetes and dementia 
 
 
 
The model for cardiovascular events was adjusted for age, gender, ethnicity, BMI, duration of diabetes therapy, HbA1c, smoking status (ever/never), alcohol 
use (ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, liver disease, heart failure, hypertension, 
neuropathies, Parkinson’s disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, valvular heart disease, history of MI), 
medications (insulin, sulphonylureas, other oral hypoglycemics, beta blockers, calcium channel blockers, loop diuretics, thiazide diuretics, anticoagulants, 
antiplatelets, cholesterol-lowering medications, ACE-i), dementia drugs 
 
 Number of events, n Adjusted HR (95% CI) 
Up to one-year follow-
up 
Adjusted HR (95% CI) 
12-60 months follow-up 
 Dementia, no 
hypoglycemia 
(n=6134) 
Dementia, hypoglycemia 
(n=1679) 
Complete case analysis (n=5607) 
Adverse events      
Cardiovascular (composite) 815 271 2.00 (1.61 to 2.48) 1.11 (0.85 to 1.47) 
MI 311 119 2.24 (1.59 to 3.15) 1.28 (0.86 to 1.91) 
Stroke 543 163 1.80 (1.37 to 2.36) 1.01 (0.71 to 1.43) 
Falls & Fractures 
(composite) 1771 555 
1.94 (1.67 to 2.24)  1.16 (0.97 to 1.40) 
Falls 1640 514 1.96 (1.69 to 2.29) 1.10 (0.91 to 1.34) 
Fractures 720 207 1.62 (1.25 to 2.08) 1.09 (0.83 to 1.43) 
Mortality 3860 1370 2.36 (2.09 to 2.67)  1.33 (1.19 to 1.48) 
This article is protected by copyright. All rights reserved.
   
 
  
The model for falls and fractures was adjusted for age, gender, ethnicity, BMI, duration of diabetes management, HbA1c, smoking status (ever/never), alcohol 
use (ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, COPD, liver disease, inflammatory bowel 
disease, heart failure, hypertension, neuropathies, osteoporosis, previous fractures, Parkinson’s disease, peripheral vascular disease, renal disease, 
retinopathy, rheumatoid arthritis, thyroid disease, valvular heart disease, history of cancer that metastasises to the bone), medications (bone protection 
medications, insulin, sulphonylureas, other oral hypoglycemics, hypnotics, antipsychotics, antidepressants, beta blockers, calcium channel blockers, loop 
diuretics, thiazide diuretics, anticoagulants, antiplatelets, cholesterol-lowering medications, steroids, Parkinson’s medications, ACE-i), dementia drugs 
 
The model for mortality was adjusted for age, gender, ethnicity, BMI, duration of diabetes management, HbA1c, smoking status (ever/never), alcohol use 
(ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, COPD, liver disease, heart failure, hypertension, 
neuropathies, Parkinson’s disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, valvular heart disease, history of MI, history 
of cancer that metastasises to the bone), medications (insulin, sulphonylureas, other oral hypoglycemics, beta blockers, calcium channel blockers, loop 
diuretics, thiazide diuretics, anticoagulants, antiplatelets, cholesterol-lowering medications, ACE-i), dementia drugs 
 
MI=myocardial infarction, ACE-i= angiotensin-converting-enzyme inhibitor, COPD=chronic obstructive pulmonary disease 
HR=Hazard Ratio, 95% CI=95% Confidence Interval 
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Table 3. Target trial 2 – dementia as an effect modifier 
 
 
 
The model for cardiovascular events was adjusted for age, gender, ethnicity, BMI, duration of diabetes therapy, HbA1c, smoking status (ever/never), alcohol 
use (ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, liver disease, heart failure, hypertension, 
neuropathies, Parkinson’s disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, valvular heart disease, history of MI), 
medications (insulin, sulphonylureas, other oral hypoglycemics, beta blockers, calcium channel blockers, loop diuretics, thiazide diuretics, anticoagulants, 
antiplatelets, cholesterol-lowering medications, ACE-i) 
 
 Number of events, n Adjusted HR (95% CI) 
Up to one-year follow-
up 
Adjusted HR (95% CI) 
12-60 months follow-up 
 Dementia, 
hypoglycemia 
(n=1679) 
Hypoglycemia, no 
dementia (n=12180) 
Complete case analysis (n=11683) 
Adverse events      
Cardiovascular (composite) 271 2297 1.14 (0.95 to 1.36) 0.91 (0.71 to 1.17) 
MI 119 1366 0.84 (0.64 to 1.10) 0.70 (0.75 to 1.00) 
Stroke 163 1097 1.41 (1.12 to 1.78) 1.22 (0.89 to 1.69) 
Falls & Fractures 
(composite) 555 2642 
1.72 (1.51 to 1.96) 1.71 (1.44 to 2.04) 
Falls 514 2266 1.82 (1.59 to 2.09) 1.69 (1.40 to 2.03) 
Fractures 207 1208 1.36 (1.09 to 1.71) 1.39 (1.08 to 1.80) 
Mortality 1370 6142 1.27 (1.15 to 1.41)  2.15 (1.94 to 2.37) 
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The model for falls and fractures was adjusted for age, gender, ethnicity, BMI, duration of diabetes management, HbA1c, smoking status (ever/never), alcohol 
use (ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, COPD, liver disease, inflammatory bowel 
disease, heart failure, hypertension, neuropathies, osteoporosis, previous fractures, Parkinson’s disease, peripheral vascular disease, renal disease, 
retinopathy, rheumatoid arthritis, thyroid disease, valvular heart disease, history of cancer that metastasises to the bone), medications (bone protection 
medications, insulin, sulphonylureas, other oral hypoglycemics, hypnotics, antipsychotics, antidepressants, beta blockers, calcium channel blockers, loop 
diuretics, thiazide diuretics, anticoagulants, antiplatelets, cholesterol-lowering medications, steroids, Parkinson’s medications, ACE-i) 
 
 
The model for mortality was adjusted for age, gender, ethnicity, BMI, duration of diabetes management, HbA1c, smoking status (ever/never), alcohol use 
(ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, COPD, liver disease, heart failure, hypertension, 
neuropathies, Parkinson’s disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, valvular heart disease, history of MI, history 
of cancer that metastasises to the bone), medications (insulin, sulphonylureas, other oral hypoglycemics, beta blockers, calcium channel blockers, loop 
diuretics, thiazide diuretics, anticoagulants, antiplatelets, cholesterol-lowering medications, ACE-i) 
 
MI=myocardial infarction, ACE-i= angiotensin-converting-enzyme inhibitor, COPD=chronic obstructive pulmonary disease 
HR=Hazard Ratio, 95% CI=95% Confidence Interval 
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Figure 1.  Schematic presentation of study 
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Figure 2. Patient flowchart 
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